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ABSTRACT: Pulmonary emphysema was induced in rats by a single intratracheal 
instillation of pancreatic elastase. The short-term effects of elastase instillation on 
basement membrane components were evaluated using immunohistochemical and 
biochemical methods.
Lung alveoli showed a decrease in heparan sulphate proteoglycan content (espe­
cially of its heparan sulphate chains) 3 h to 7 days after induction. Type IV colla­
gen, laminin and fibronectin were not affected. The glycosaminoglycan content of 
the lung was decreased during the First 3 days after induction, while the gly­
cosaminoglycan concentration in urine was increased during the first 4 days by an 
increase of heparan sulphate and derma tan sulphate. The increase in urinary gly­
cosaminoglycan content was positively correlated with the extent of emphysema 
developed after 40 days.
We conclude that proteoglycans are target molecules for elastase, and may be 
involved in the pathogenesis of emphysema.
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The connective tissue of the lung parenchyma plays 
an important role in the functioning of the respiratory 
system. Alterations in the connective tissue skeleton are 
believed to be important in several chronic lung diseases, 
such as emphysema and fibrosis [1, 2]. Major compo­
nents of lung extracellular matrix are elastin, collagen 
and proteoglycans (PGs). PGs consist of a core protein, 
to which one or more glycosaminoglycan (GAG) chains 
are covalently attached. GAGs are polysaccharides which 
are strongly negatively-charged due to an abundance of 
carboxylic and/or sulphate groups. In the alveolar wall, 
two types of PGs are predominantly present: decorin and 
perlecan. Decorin is a small dermatan sulphate (DS) 
proteoglycan which is associated with collagen fibrils 
[3-6], and perlecan is a heparan sulphate proteoglycan 
(HSPG) present in basement membranes [6-9].
The predominant theory on the pathogenesis of emphy­
sema is the protease/antiprotease concept [10-12], This 
concept emanates from a relative excess of proteases 
(elastases), due to an increase of proteases and/or a de­
crease of protease inhibitors. An excess of proteases leads 
to the degradation of the connective tissue skeleton and 
ultimately to emphysema. One has almost exclusively 
focused on elastin as the target molecule for proteases, 
in part because the most studied animal model for 
emphysema is elastase-induced emphysema. Elastase, 
however, is also capable of degrading a number of other 
proteins, including PGs, fibronectin and some types of 
collagen in vitro [13, 14]. Digestion of PGs may be of 
particular importance, since: 1) PGs are involved in fib-
rillogenesis of collagen and elastin, and can modulate 
their mechanical characteristics [3, 4]; 2) PGs interact 
with and modulate a number of molecules, including 
growth factors and extracellular matrix molecules [15- 
21]; and 3) GAGs can act as powerful protease inhibi­
tors, e.g. for leucocyte elastase and cathepsin G [22-24]. 
In addition, the close association of PGs with structural 
elements in the alveolar wall (e.g. basement membranes, 
collagen fibrils and elastin fibres) indicates a protective 
role [6, 25-28].
In this respect, we studied the effects of an emphysema- 
inducing dose of pancreatic elastase in rats on perlecan 
(the core protein as well as the heparan sulphate (HS) 
side-chains) and on other extracellular matrix compo­
nents of the alveolar wall by immunohistochemical and 
biochemical methods. Additionally, we investigated the 
excretion of GAG into the urine following elastase treat­
ment.
Material and methods
1,9-Dimethylmethylene blue (80% pure) was purchased 
from Aldrich Chemical Co., Bomem, Belgium; Universal 
Gel/8 1% agarose gels from Ciba-Corning GmbH, 
Femwald, Germany; Aquamount from BDH Ltd, Poole 
UK; halothane from Apharmo, Arnhem, The Netherlands; 
pentobarbitol (Narcovet) from ICI-Farma, Rotterdam, 
The Netherlands; diethylaminoethyl (DEAE)-Sepharose 
Fast Flow from Pharmacia, Uppsala, Sweden; Azure A,
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Tween-20, whale cartilage chondroitin 4-sulphate, bovine 
kidney HS, porcine pancreatic elastase, bovine serum 
albumin (BSA), fluorescein isothiocyanate (FITC)-con- 
jugated goat anti-rabbit immunoglobulin G (IgG), FTTC- 
conjugated goat anti-mouse immunoglobulin M (IgM) 
and affinity purified rabbit anti-laminin IgG from Sig­
ma Inc., St. Louis, MO, USA; tetra-methylrhodamine 
isothiocyanate (TRITC)-conjugated goat anti-mouse Ig 
and FITC^conjugated donkey anti-goat IgG from Nordic 
Immunological Laboratory, Capistrano Beach, CA, USA; 
affinity purified goat anti-human type IV collagen anti­
bodies from Southern Biotechnology Ass, Inc., Birmingham, 
AL, USA; affinity purified rabbit anti-human fibronectin 
IgG from Dako, Glostrup, Denmark. Rabbit anti-basement 
membrane HSPG and monoclonal mouse anti-HS (JM403) 
antibody were obtained and characterized as described pre­
viously [9, 29],
[35S]GAGs (specific activity 6.105 Bq-^tg1 GAG) were 
obtained from rats injected twice i.p. with 37,000 Bq 
Na235S04-g' 1 body weight with a 4 h time span between 
each injection. Four hours after the second injection, the 
rats were sacrificed and the soft tissues (i.e. liver, kid­
ney, intestine etc.) removed. GAGs were extracted by 
alkaline borohydride.
Animal accommodation
Animals were accommodated in groups of three and 
fed ad libitum. For urine collection, animals were ac­
commodated separately in metabolic cages. To avoid 
stress factors, animals were habituated to these cages for 
7 days before treatment.
Induction o f  pulmonary emphysema
Male Wistar rats (weight 200±10 g) were anaesthetized 
with 3% halothane, intubated and artificially ventilated 
according to M auderly  [30]. Rats were hyperventilat­
ed, to stop intrinsic breathing for a few seconds, and 
were instilled during this time span with 0.2 IU pancre­
atic elastase-g' 1 body weight in 0.5 ml saline. Control 
animals were instilled with 0.5 ml saline. After instil­
lation, rats were ventilated until they awoke.
Histology
Animals were sacrificed by an overdose of pentobar­
bital injected i,pt For morphometric studies, lungs were 
dissected and fixed with 2% glutaraldehyde in 150 
mmol- / 1 phosphate buffer (pH 7.2), administered 
through a polyethylene catheter inserted into the trachea 
at a pressure of 25 cm H20. After 30 min, lungs were 
fixed for an additonal 24 h in 2% gluteraldehyde, dehy­
drated and embedded in paraffin. Tissue sections (6 |im) 
were contrasted using the trichrome staining of G oldner 
[31]. To assess the degree of emphysema, the mean lin­
ear intercept was determined using a Mop-videoplan 
image analyser (Kontron GmbH, Eching, München, 
Germany). Images of tissue sections were projected on 
a digitization tablet on which a line raster was applied. 
Of each lung, a total of 400 intercepts, derived from 
two sections, were measured.
For immunofluorescence studies, lungs were dissected, 
and inflated through a polyethylene catheter inserted 
into the trachea with phosphate-buffered saline (PBS) at 
a pressure of 25 cm H20. PBS-filled lungs were frozen 
in liquid nitrogen and stored at -70°C. Cryosections (6 
\im) were stored at -70°C. Cryosections were rehydrat­
ed for 10 min in PBS, containing 1% BSA. Antibodies 
were applied for 1.5 h in PBS containing 1% BSA. 
After each antibody, incubation sections were washed in 
PBS (3x5 min). Anti-HS antibodies and all second­
ary antibodies were used at a dilution of 1:100. All 
other antibodies were used at 1:50, Double staining was 
performed using fluorescein- and rhodamine-labelled 
secondary antibodies. Sections were embedded in aqua- 
mount and examined on a Zeiss axioskop photomicro­
scope (Carl Zeiss, Oberkochen, Germany). Observations 
were made by two blinded observers. A "strong1' decrease 
was defined by large areas in the section showing no 
specific antibody staining. "Weak" was defined by some 
small areas in the section which showed a reduced 
immunostaining. "Moderate" was defined as a moder­
ate number of areas (between strong and weak) show­
ing a clear, but not complete, absence of staining.
Purification o f urinary glycosaminoglycans
Rat urine was collected one day before elastase in­
stillation, then daily for 9 days and finally on Day 19 
post instillation. GAGs were purified from urine by anion 
exchange chromatography. Urine was centrifuged at 
2,000xg for 10 min (at 4°C), and 20 ml of the super­
natant was diluted to 50 ml by adding 10 mmol-/*1 
Tris-HCl (pH 6.8). The diluted samples were loaded onto 
a column of 5x0.5 cm containing 0.5 ml DEAE-Sepha- 
rose Fast Flow. After an initial wash with 3 ml 0.2 
mol*/’1 NaCl/10 mmol*/-1 Tris-HCl (pH 6.8), GAGs were 
eluted with 4 ml 2 mol-/-1 NaCl/10 mmol-/'1 Tris-HCl (pH 
6.8). Recovery of GAGs was monitored by adding 9.105 
Bq [35S]GAG to the urine, and was between 72-101%.
Extraction o f  lung glycosaminoglycans
GAGs were extracted according to a modified method 
of Hoffmann [32], Pleura, large airways and blood ves­
sels were removed. The remaining tissue was defatted 
in 20 vol. acetone at -20°C for 16 h, followed by extrac­
tion with 20 vol. ether/methanol (1:1) at 4°C for 24 h. 
The material was dried, pulverized with a glass rod and 
suspended in 40 vol. (w/v) of 0.75 mol-/*1 NaOH/lO 
mmol- /1 NaBH4. After 1 h at 73°C, the mixture was 
neutralized with 6 mol*/’1 HC1 and 100% (w/v) trichlo­
roacetic acid was added to a final concentration of 6%. 
After 1 h at 4°C, and centrifugation (15 min, 2,000x 
g, 4°C), the pellet was dissolved in 0.1 mol*/-1 NaOH. 
The protein concentration was determined according to 
Lowry et a l  [33]. To the supernatant, 5 vol. of ethanol 
(100%) was added and after 16 h at -20°C the mix­
ture was centrifuged (30 min, 15,000xg, 4°C). The 
precipitated GAGs were dried and dissolved in de­
mineralized water. GAGs were quantified using the 1,9- 
dimethylmethylene blue (DMMB) assay (see below).
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Quantification o f  sulphated glycosaminoglycans
The content of sulphated GAGs was determined using 
the DMMB assay of F arn d ale and co-workers [34, 35]. 
To 100 |il sample (urine or lung extract) 2.5 ml of DMMB 
reagent was added and the absorbance at 525 nm was 
measured directly. The DMMB reagent consists of 48 
jimol-/'1 DMMB (initially 48 nmol DMMB was dissol­
ved in 5 ml 96% ethanol), 42 mmoW*1 glycine and 42 
mmol-/-1 NaCl, adjusted to pH 3.0 with 1 mol*/*1 HCL 
Chondroitin 4-sulphate was taken as a standard and in­
cluded within each series of assays. For calculations we 
used second order regression analysis.
Quantification o f  urinary heparan sulphate content
Urinary HS content was determined by a nonequilib­
rium inhibition enzyme-linked immunosorbent assay 
(ELISA). To 100 ^1 sample 100 |xl anti-HS (JM403) 
(dilution 1/40,000 in Tris-buffered saline (pH 7.2) con­
taining 0.1% Tween-20 (TBST) and 1% BS A) was added. 
After 16 h at 4°C, 100 |il of this mixture was transferred 
to a HS-coated microtitre plate, and free anti-HS anti­
bodies were allowed to bind to the coated HS for 2 h. 
The plate was washed with TBST and 100 pi alkaline 
phosphatase conjugated anti-mouse Ig, at a dilution of
1/2,000 in TBST/BSA was added. After 1 h, the plates 
were washed with TBST and alkaline phosphatase was 
detected using 1 mg-mH dinitrophenyl phosphate in 1 
mol*/-1 diethanolamine (pH 9.8) containing 50 mmol-/-1 
MgCL,. Absorbance was measured at 405 nm. Bovine 
kidney HS was taken as a standard within each series of 
assays.
Characterization o f  urinary glycosaminoglycans
Purified urinary GAGs were separated on agarose gel 
using 0.1 mol*/'1 barium acetate (pH 5.0) as electrophor­
esis buffer. GAGs were visualized using a combined 
azure A silver-staining [36].
Creatinine assay
Creatinine was measured using the alkaline picrate 
method, based on the Jaffe reaction (Sigma, procedure
No. 555).
Statistical analysis
Intergroup comparison was calculated using Student's 
t-test. Correlation analysis was performed using Pearson's 
product moment correlation test [37]. All values are 
given as mean±sEM. Data were normally distributed.
Fig. 1. -  Immunofluorescence of lung tissue stained with anti-heparan sulphate (HS) antibodies 3 h after treatment of rats with elastase: A) detail 
and C) overview; or saline: B) detail and D) overview* Note the abrupt changes in immunostaining (see arrows). (Internal scale bar = 100 \m ).
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Pig. 2. — Immunofluorescence double staining of rat lung tissue 1 day after elastase treatment. Panels A, C, E and G show staining for heparan 
sulphate (HS) and panels B, D, F and H staining for heparan sulphate proteoglycan (HSPG) core-protein, type IV collagen, laminin and fibronectin, 
respectively. Note that only staining for HS and HSPG is reduced or absent compared to lung of saline-treated rats (see fig. 1 for HS). (Internal 
scale bar = 100 |im).
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Table 1. -  Effects of elastase treatment on immune 
staining of alveolar basement membrane components
Time after elastase treatment
3 h 1 d 2d 3 d 5 d 7 d
HS ¿41 l i 1 I
HSPG u 1 I — —
(core protein)
Laminin — — ND ND ND
Fibronectin — — — ND ND ND
Type IV 
collagen — — — ND ND ND
HS: heparan sulphate; HSPG: heparan sulphate proteoglycan; 
ND: not determined; no effect; X: weak decrease; X-l: 
moderate decrease; i i l :  strong decrease*
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Fig. 3. -  Urinaiy glycosaminoglycan (GAG) content after intratra­
cheal elastase instillation, o: saline-treated rats; • :  elastase-treated 
rats, *: p<0.01; **: p<0.005; ***: p<0.0005. Numbers of rats are 
indicated in brackets.
Results
General histology
Three hours after intratracheal instillation of porcine 
pancreatic elastase, we observed an infiltration of in­
flammatory cells into the lung accompanied by haemor­
rhages and pulmonary oedema, indicating acute lung 
injury. This stage persisted for about 3 days. Lung mor­
phology returned to normal after 5-7 days. Two weeks 
after elastase treatment the first emphysematous lesions 
could be observed. Forty days after elastase treatment 
the mean linear intercept was increased to 81.7±2.3 |im 
(n=17), compared to 58.6±1.2 )xm (n=8) for controls.
Immunofluorescence studies o f  basement membrane com­
ponents
In lung parenchyma, HS is linearly distributed in alve­
oli in accordance with its presence in basement mem­
branes (fig. 1), Table 1 summarizes the effects of elastase 
on basement membrane components. Three hours after 
elastase treatment, large areas of the lung lacked HS 
staining (fig. 1A and C). In some cases, one alveolus 
was completely devoid of HS, whilst in the adjacent alve­
olus staining was normal (fig, 1A). At places where HS 
staining was reduced or absent, staining for the core pro­
tein of HSPG was also reduced, although to a lesser 
extent (fig. 2A and B). After 5 days, most HS staining 
had returned. At all times, staining for type IV colla­
gen, laminin and fibronectin was normal, even at places 
where HS staining was absent (fig. 2C-H). Attempts to 
localize elastase using commercial antibodies were un­
successful. The elastase used was devoid of HS digest­
ing activity, as was demonstrated by incubation of HS 
with elastase followed by assaying the molecular mass 
of HS by polyacrylamide gel electrophoresis (data not 
shown).
Lung and urinary GAG content after elastase instillation
During the first 3 days after elastase treatment, the con­
tent of GAGs in lung tissue was significantly decreased
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Fig. 4. -  Separation of diethylaminoethyl (DEAE)-purified urinary 
gly cos aminogly cans (GAGs) of an individual rat by agarose gel elec­
trophoresis. Lane 1: 1 day before; lanes 2 and 3: 1 and 3 days after 
elastase treatment, respectively; M: marker GAGs; HS: heparan sul­
phate; DS: dermatan sulphate; CS: chondriotin sulphate. The amounts 
of urinary GAGs applied to the gel were derived from urine samples, 
containing 1,25 jig creatinine. Note the increase of HS and DS after 
elastase treatment (lanes 2 and 3).
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Fig. 5. -  Urinary heparan sulphate (HS-epitope JM403) content after 
intratracheal elastase instillation, o: saline-treated rats; •:  elastase- 
treated rats (n=6). *: p<0.01. HS content was determined by an 
enzyme-linked immunosorbent assay (ELISA) using bovine kidney HS 
as a standard, Note that the unit HS-epitope JM403-mg'' creatinine is 
arbitrary; it reflects the amount of the HS-epitope JM403 corresponding 
to I [Xg bovine kidney HS.
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Fig. 6. -  Correlation of the mean linear intercept (MLI) measured 40 
days after treatment and the urinary GAG excretion during the first 4 
days after treatment (pcO.OOOl; r=0.85). o: saline-treated rats; •:  
elastase-treated rats.
(2.8±0.07 (n=8) versus 4.6±0.2 (n=8) |ig GAG-mg-1 
protein, for saline-treated rats (pcO.OOOl)). Thereafter, 
no significant changes could be observed.
The concentration of GAGs in urine was significantly 
increased during the first 4 days after elastase treatment, 
with a maximum at Day 1 (fig. 3). Agarose gel elec­
trophoresis of the GAGs shows that in addition to the 
HS the DS excretion was also markedly increased after 
elastase treatment, with a maximum at Day 1 (fig. 4). 
ELISA of purified urinary GAGs displayed a signifi­
cant increase in HS (JM403 epitope) 1-3 days after elas­
tase treatment, with a maximum level at Day 3 (fig. 5). 
The apparent discrepancy between the day of peak level 
of HS measured by ELISA and of HS determined by 
agarose electrophoresis may be explained by the specifi­
city of the JM403 antibody. This antibody recognizes 
only HS from basement membranes and not HS from 
other sources, such as those located at the cell surface 
[29], which are probably also removed from the alveoli 
as a result of elastase treatment. Therefore, perhaps the 
HS at Day 1 (lane 2 , fig. 4) consisted mainly of non­
basement HS, not detected by the JM403 antibody. 
This, however, requires further study.
The extent of emphysema, measured as the increase 
of mean linear intercept 40 days after induction, was posi­
tively correlated to the concentration of GAGs in the 
urine during the first 4 days after induction (the time at 
which GAG excretion was increased) (fig. 6).
Discussion
The predominant theory on the pathogenesis of em­
physema emanates from a disturbance of the protease/ 
antiprotease balance, favouring the proteases [10- 12]. 
Elastin has been regarded as the target molecule in the 
extracellular matrix. In pancreatic elastase-induced em­
physema, elastin breakdown occurs [38]. Elastase, how­
ever, is an indiscriminate enzyme, capable of the in vitro
degradation of many proteins, including proteoglycans, 
collagen, fibronectin and laminin. Little is known about 
the in vivo effect of elastase on these molecules. In this 
study, we have shown that, in particular, proteoglycans 
are target molecules for instilled elastase in rat lungs. 
Fibronectin, type IV collagen and laminin were not affec­
ted, although small changes may have gone undetected 
using immunohistochemistry. These results are in ac­
cordance with an electron microscopical study on pan­
creatic elastase-induced emphysema showing no change 
in laminin or appearance of the basement membrane, 
but elimination of HS [39, 40]. The observation that in 
places where HS staining is absent staining for HSPG 
core protein is only reduced, can be explained by in­
complete cleavage of the HSPG core protein. Since all 
three HS chains are attached to the N-terminus of the 
protein [41, 42], one cut at this end of the protein will 
release all HS chains, whereas a large part of the core 
protein, and thus most of the epitopes for the polyclonal 
anti-HSPG antibodies, remain present in the basement 
membrane.
It has been postulated that proteases can induce em­
physematous lesions only if they possess elastolytic 
activity [43]. However, several animal models for emphy­
sema exist where there is no elastin breakdown, includ­
ing emphysema induced by CdCl2 [44, 45], by 90% 
oxygen [46], or by collagenase [47], and genetic emphy­
sema in the tight-skin mouse [48]. In addition, leuco­
cyte elastase, implicated in emphysematogenesis in man, 
has been reported to lack elastolytic activity [49]. There 
is no consensus on elastin breakdown in human pulmo­
nary emphysema [50-52]. We suggest, as an alternative 
possibility, that degradation of proteoglycans (e.g. by 
leucocyte elastase) is associated with the onset of the 
disease.
Proteoglycans are implicated in a number of functions 
important for the integrity of the extracellular matrix, 
which is compromised in emphysema. The GAGs are 
powerful inhibitors of proteases, including leucocyte 
elastase [20, 22, 53], and prevent leucocyte elastase- 
induced emphysema in mouse and rat [23, 24]. Ultra- 
structurally, proteoglycans are present around collagen 
fibrils, elastin fibres and in basement membranes [6, 25,
27, 28]. Removal of proteoglycans associated with elas­
tin facilitates the digestion of the latter [54-56]. In addi­
tion, proteoglycans are involved in the fibrillogenesis of 
the major fibrillar components, collagen and elastin, and 
may influence their mechanical characteristics [3, 4, 57]. 
Proteoglycans, especially HSPGs, bind and modulate 
growth factors, including basic fibroblast growth factor 
bFGF), interferon-y, interleukin-8 and transforming 
growth factor-p [16-20]. In lung parenchyma, degra­
dation of HS by heparitinase results in the release of 
bFGF [58]. Hence, removal of proteoglycans from the 
alveolar wall, e.g. by proteolysis, may result in a distur­
bance of the extracellular matrix, which may ultimately 
lead to emphysematous lesions. Intratracheal instillation 
of hyaluronidase (which digests some types of GAG) to­
gether with 60% oxygen results in airspace enlargement
after 4 days [59].
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The disappearance of HSPG in the lung is accompa­
nied by an increase of GAGs in the urine. This increase, 
observed during the first 4 days after elastase instilla­
tion, is positively correlated with the increase of the 
mean linear intercept, an indicator for parenchymal des­
truction, 40 days after instillation. Increase of urinary 
GAGs may, therefore, be an indicator for tissue destruc­
tion and may be of value in predicting the long-term 
outcome of acute tissue destruction (e.g. during exacer­
bations).
In conclusion, intratracheal instillation of pancreatic 
elastase in rats results in digestion of proteoglycans but 
not of other basement membrane components. The con­
comitant increase in urinary GAGs is positively corre­
lated with the degree of emphysematous lesions observed 
after 40 days. The vulnerability of PGs toward proteases 
may be of importance in the pathogenesis of emphyema.
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